

1 **Extracellular vesicles in the pathogenesis of *Campylobacter jejuni***

2

3 Jeanne Malet-Villemagne^{a,*}, Jasmina Vidic^{a,*}

4

5 ^a Université Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, Domaine de Vilvert, 78350

6 Jouy en Josas, France

7

8 *Corresponding authors: jeanne.villemagne@gmail.com; jasmina.vidic@inrae.fr

9

10 **Abstract**

11 Bacteria in genus *Campylobacter* are the leading cause of foodborne infections worldwide.

12 Here we describe the roles of extracellular vesicles in the pathogenesis of these bacteria and

13 current knowledge of vesicle biogenesis. We also discuss the advantages of this alternative

14 secretion pathway for bacterial virulence.

15

16 **Keywords**

17 Extracellular vesicles; Secretion system; Virulence factors; Gram-negative bacteria;

18 *Campylobacter*.

19

20 1. Introduction

21 *Campylobacter* is a genus of spirally curved, Gram-negative, non-fermentative,
22 microaerophilic, and non-spore-forming zoonotic bacteria. The majority of *Campylobacter*
23 species are characterized by their rapid, corkscrew-like motility, which is mediated by an
24 unsheathed, polar flagellum at one or both ends. Since the recognition of the genus
25 *Campylobacter* in 1991, its taxonomy has undergone numerous modifications. According to
26 the most-recent taxonomic structure, there are currently 50 species of *Campylobacter* and 16
27 subspecies yet to be described [1], although the classification scheme of the WHO recognizes
28 only 17 species and 6 subspecies [2]. Of these, the four thermophilic species *Campylobacter*
29 *jejuni*, *Campylobacter coli*, *Campylobacter lari*, and *Campylobacter upsaliensis* are those most
30 commonly associated with human infection.

31 *Campylobacters* are the most common cause of foodborne bacterial gastroenteritis
32 worldwide, with 1.5 million cases estimated annually in the United States [3] and 137,107
33 cases reported in Europe in 2022 (UK non-included) [4]. The overall economic burden of
34 campylobacteriosis was estimated at about €3 billion in the EU [5], and US\$ 4 billion in the US
35 annually [6]. More than 90% of human campylobacteriosis cases are caused by *C. jejuni* and *C.*
36 *coli*, with the vast majority (over 80%) due to *C. jejuni* [7]. Unlike *Salmonella* or *Listeria*,
37 *Campylobacter* spp. are not able to multiply within foods and are not associated with large
38 outbreaks. More than 90% of cases of human campylobacteriosis are sporadic.

39 Identification of campylobacters is challenging using traditional microbiological
40 culturing techniques. These bacteria are considered to be fastidious microorganisms because
41 they can neither ferment nor oxidize carbohydrates. Their optimum growth temperature is
42 between 37–42°C, but their culturing requires special medium and conditions such as the
43 addition of blood to a culture broth and mandatory microaerobic environments [8]. The

44 biochemical/phenotypical characterization of campylobacters is also difficult because they
45 can change their distinctive “S”-shape into a coccoid form. Given these challenges, the
46 increased incidence of illnesses associated with these bacteria, and the inadequacies of
47 current therapies, there is an urgent need for the development of new strategies for control
48 and treatment. Such strategies will draw inspiration from studies of *Campylobacter*’s ability
49 to invade, replicate within the host, and survive in the face of stressors, research that is rapidly
50 improving our understanding of its dissemination, ability to escape from host immune
51 defenses, and adaptation to different environments.

52 In this review, we first introduce the main virulence factors involved in various steps of
53 infection by *Campylobacter*, and then present a synthesis of current knowledge concerning
54 the role of bacterial extracellular vesicles (BEVs) in its pathogenesis. We discuss the
55 importance of BEVs in this bacterium’s lifestyle, dissemination, and infection process,
56 particularly given the absence of other genes for prototypical secretion systems in the genome
57 of *Campylobacter*.

58


59 **2. Campylobacteriosis and virulence of campylobacters**

60 Campylobacters, like other bacteria, have developed complex systems for exporting effectors
61 and virulence factors in order to adapt to adverse conditions or colonize new habitats. When
62 exposed to an unfavorable environment, campylobacters produce virulence factors that can
63 also act as antimicrobial resistance factors or niche factors at various steps along the food
64 chain or during infection. In addition, in the presence of oxygen or under antibiotic pressure,
65 *C. jejuni* may enter a “persister state” [9], a non-growing state in which
66 reduction/dysregulation in metabolic processes enables bacterial cells to survive lethal stress
67 conditions. The metabolic burst in the persister phenotypic variant has been proposed to

68 result from a reduction in membrane potential due to remodeling of the electron transport
69 chain [9], which prevents hyperpolarization of the inner membrane and curbs intracellular
70 alkalization. In the persister state, cells of *C. jejuni* demonstrate reduced respiration and
71 nutrient transport and considerable modulation of gene expression; however, when
72 environmental conditions become favorable again, these bacteria may return to their original
73 phenotype and cause infection [9].

74 This zoonosis is transmitted through consumption of under-cooked poultry meat and
75 meat products (up to 80% of cases), as well as raw milk, shellfish, vegetables, and contact with
76 animals [10]. The majority of cases of campylobacteriosis are reported during the summer
77 season, likely associated with outdoor barbecues [11]. However, campylobacters can also
78 survive in water, and infection may occur following contact with contaminated water during
79 recreational activities. Clinical symptoms of illness range from self-limiting diarrhea to severe
80 inflammatory and bloody diarrhea, sometimes associated with systemic issues. Most of the
81 time, symptoms follow an incubation period of 2 to 5 days and are limited to gastroenteritis
82 with diarrhea, fever, abdominal cramps, and vomiting lasting from 2 to 10 days [7]. The
83 infective dose in a human host is low, around 500–800 bacteria [12]. Even if the majority of *C.*
84 *jejuni* infections remain uncomplicated, this pathogen is the main infectious agent identified
85 in peripheral neuropathies such as Guillain-Barré syndrome [13] or Miller-Fisher syndrome,
86 which can lead to death in 2–12% of patients, depending on their age. Finally,
87 campylobacteriosis may result, in rare cases, in intestinal complications (colitis, appendicitis,
88 irritable bowel syndrome, colorectal cancer, Barrett’s esophagus) or systemic infections
89 (endocarditis, pneumonia, neonatal sepsis). The true incidence of campylobacteriosis is
90 estimated to be under-reported by a factor of 10, mainly due to underdiagnosis, misdiagnosis
91 or improper sample collection and testing [14].

92 The clinical presentation of *Campylobacter* infections is influenced by a range of virulence
 93 factors used by the bacterium to target host cells, adhere to mucus, invade epithelial cells,
 94 and cause cell damage. To date, the pathogenesis of *C. jejuni* remains poorly understood due
 95 to the complexity of the genetic mechanisms involved and a lack of appropriate animal models
 96 for research. However, multiple virulence factors expressed by this bacterium are implicated
 97 in crucial steps of pathogenesis, as illustrated in Fig. 1.



98
 99 **Figure 1. The process of infection by the intestinal pathogen *Campylobacter jejuni* and the**
 100 **virulence factors implicated.** The infectious process of *C. jejuni* begins when the bacteria
 101 reach the intestinal epithelial cells of the host and then adhere to and invade those cells. Two
 102 models are presented for *C. jejuni*'s migration through the epithelium (violet / sky blue). Once
 103 internalized, *C. jejuni* produces CDT toxins (cytolethal distending toxins) and proteases, which
 104 provoke cell death and inflammation. Then, the bacteria may survive or be cleared from the
 105 host. Virulence factors are noted in green.

106

107 **2.1. Reaching target host cells**

108 For enteric pathogens, a key step of infection is colonization of the intestinal epithelial cells.
109 This process requires the ability to penetrate the mucus layer covering epithelial cells in order
110 to reach the target cells and then internalize. *Campylobacter* species are naturally able to
111 swim very rapidly in viscous environments due to their helical shape and amphitrichous
112 flagella [15]. Indeed, *C. jejuni* has been documented to travel at a higher velocity in mucus
113 than most other bacteria (55 to 100 $\mu\text{m}\cdot\text{s}^{-1}$) [16].

114 Given the crucial role of the flagellum in the colonization process, the flagellar proteins are
115 considered to act as bacterial virulence factors. In addition to motility, the flagellum is involved
116 in biofilm formation, adhesion, internalization, and protein secretion [17,18]. The basic
117 structure of a bacterial flagellum consists of an extracellular filament connected via a hook to
118 a basal body formed of rings and a rod. The basal body complex comprises the MS ring (FliF
119 protein), the C ring rotor (FliG, FliM, FliN, FliY), the P-ring in the peptidoglycan layer and the L-
120 ring in the outer membrane (Flg I and FlgH, respectively, described in other Gram-negative
121 bacteria), the rod (FlgF and FlgG), and a motor (MotA, MotB) responsible for the rotation
122 force. This assemblage anchors the flagellum to the bacterial envelope with the help of a hook
123 (FlgE) and surrounds the type III secretion system (T3SS) localized in the inner membrane. The
124 flagellar T3SS is composed of the proteins FlhA, FlhB, FliO, FliP, FliQ, and FliR, and exports distal
125 flagellar fragments through the membranes to construct the extracellular filament, formed by
126 the two glycosylated flagellins FlaA and FlaB [19]. The monomers at the distal end of the
127 filament are covered with the flagellar capping protein FliD [20].

128 A bacterium's route and directional changes during swimming are determined by the
129 rotational direction of the flagellum, which alternates between clockwise and counter-
130 clockwise depending on extracellular signals. The rotational direction of the flagellum is
131 usually coupled to chemosensory receptors, enabling the bacterium to reach a favorable


132 environment [21]. Bacterial movement driven by gradients of oxygen, nutrients, or
133 temperature—called chemotaxis—may play an important role in both the commensal and
134 pathogenic lifestyles of *Campylobacter*. Various extracellular signals are detected by methyl-
135 accepting chemotaxis proteins (MCPs), also called transducer-like proteins (Tlps). These
136 proteins are classified into three groups (A, B, and C) depending on their structure. Novel Tlp
137 proteins were recently identified (Tlp14-25), in addition to the 13 Tlps previously described
138 [22–24]. Once the external stimuli bind to Tlps, a signal is relayed to chemotaxis proteins (Che)
139 in the cytoplasm. These proteins initiate a signal transduction cascade resulting in directional
140 rotation of the flagellum. To date, 6 Che proteins have been described in *C. jejuni* [23].
141 Notably, the loss of CheY creates bacteria that are non-motile and non-invasive. For *C. jejuni*,
142 chemotaxis is as essential as motility for reaching intestinal cells and colonizing the gut of
143 chickens and mammals [25].

144

145 **2.2. Adhesion and invasion of host cells: two models for transepithelial migration of *C.*** 146 ***jejuni***

147 After reaching the gut, *C. jejuni* must cross the mucus layer and adhere to intestinal epithelial
148 cells in order to invade them. A series of studies in human biopsies have shown that *C. jejuni*
149 is able to cross the epithelial barrier and enter underlying tissues, organs, and the bloodstream
150 [26]. However, the mechanism of this transmigration through the intestinal epithelium is still
151 debated and not well understood. To explain how *C. jejuni* is able to cross polarized epithelial
152 cells, two transmigration routes have been hypothesized: (i) the transcellular route, in which
153 bacteria cross the epithelial barrier through adhesion and cell entry at the apical pole and exit
154 at the basal pole [27], and (ii) the paracellular route, in which pathogens open cell junctions
155 using proteases like HtrA [28] and make their way between cells by adhering to basal

156 extracellular matrix components like fibronectin before finally invading a cell at the basal pole
 157 (Fig. 2). The adhesion and invasion steps of pathogenesis may therefore occur either at the
 158 apical pole or at the basal one, depending on the route taken by *C. jejuni*. Currently, studies
 159 have been converging towards the paracellular pathway, considering the importance of
 160 fibronectin-binding and HtrA-mediated adherens junctions cleavage for the internalization of
 161 *C. jejuni* [29,30].



162

163 **Figure 2. The two models hypothesized for the epithelial transmigration of *Campylobacter***
 164 ***jejuni* during infection.** In the transcellular route, bacteria adhere to and invade the apical
 165 pole of epithelial cells and exit by the basal pole. In the paracellular route, bacteria cleave cell
 166 junctions to cross the epithelial barrier between two cells, and once at the basal pole, adhere
 167 to and invade the cell.

168

169 **2.2.1. Adhesion**

170 As for many bacteria, adhesion of *C. jejuni* is a multifactorial process. Several binding factors
171 have been implicated in the successful interaction with host cells and the development of
172 disease. Depending on the transmigration route taken by the bacterium, adhesion may occur
173 either at the apical pole (adhesion to mucus or directly to epithelial cells) or at the basal one
174 (adhesion to extracellular matrix components like fibronectin).

175 Certain adhesion factors found in *C. jejuni* have been shown to promote basal adhesion to
176 fibronectin, a large and ubiquitous glycoprotein that is the main component of the
177 extracellular matrix of mammalian cells. Binding to this protein is the primary step of
178 attachment to tissue surfaces for numerous pathogens. Of the adhesins that have been found
179 to bind to fibronectin, three are of particular interest: the major outer membrane protein,
180 MOMP [31], and the outer membrane proteins CadF (*Campylobacter* spp. adhesion to
181 fibronectin) and FlpA (fibronectin-like protein A). Studies of *cadF* and *flpA* mutants have
182 revealed impairments in binding to epithelial cells, colonization of the chicken gut, and the
183 establishment of severe disease in germ-free mice [32,33]. These proteins promote adhesion
184 via their fibronectin-binding sites, which consist of a four-amino-acid motif (Phe-Arg-Leu-Ser)
185 for CadF and a nine-amino-acid motif (Trp-Arg-Pro-His-Pro-Asp-Phe-Arg-Val) for FlpA [34].

186 Other proteins enhance the adhesive properties of bacteria via their chaperone
187 activity, assisting in the folding of outer membrane proteins and thus in modifications to the
188 bacterial surface. The best example is the serine protease HtrA, a highly conserved periplasmic
189 protein displaying both protease and chaperone activity. A loss of HtrA chaperone activity
190 leads to a strong reduction in bacterial binding to epithelial cells, more so than the loss of any
191 other known adhesin [35].

192 Some proteins have been identified as adhesins but the mechanism by which they bind
193 epithelial cells is still unknown. An example of this is Peb1, the first protein identified in *C.*
194 *jejuni* as being involved in bacterial adhesion to HeLa cells and the colonization of mice [36].
195 Another example is CapA, an autotransporter protein of the outer membrane. CapA is not
196 conserved among all strains of *C. jejuni*, but when it is present this surface-exposed protein
197 plays a role in binding to epithelial cells and is required for efficient colonization of chickens
198 [37]. Some flagellar proteins seem to hold a role also in adhesion, such as FlaC which binds
199 HEp-2 cells, by an unknown mechanism [38]. Finally, mutation of the *comB3* gene (encoded in
200 the *C. jejuni* resistance plasmid pVir) was found to result in decreased adhesion and invasion
201 of INT-407 cells, [39].

202 The adhesion process also appears to depend on certain non-protein components, such
203 as polysaccharides or plasmids. *C. jejuni* can produce lipooligosaccharides (LOS) and highly
204 variable capsular polysaccharides but not lipopolysaccharides (LPS). It is through these
205 polysaccharides that the *C. jejuni* capsule participates in the processes of adherence and
206 invasion. For example, strains with mutations in three LOS synthesis genes (*wlaRG*, *wlaTB*, and
207 *wlaTC*) all displayed reduced adhesion to chicken embryo fibroblasts [40]. Interestingly, the
208 similarity between the LOS of *C. jejuni* and neuronal gangliosides is thought to explain the link
209 between *C. jejuni* and Guillain-Barré Syndrome.

210

211 **2.2.2. Cell invasion**

212 In 2001, Rivera-Amill *et al.* demonstrated that certain proteins—designated Cia for
213 *Campylobacter* spp. invasion antigens—are secreted during co-cultivation of *C. jejuni* and
214 intestinal cells [41]. More precisely, they identified a temporal association between the
215 secretion of Cia proteins and the invasion of cells by *C. jejuni*: Cia proteins are secreted after

216 30 minutes of co-culturing, at the precise moment when a rapid increase in the internalization
217 of bacteria is observed. Because the genome of *C. jejuni* lacks genes associated with a classical
218 type III secretion system, the flagellar export apparatus was identified as the likely mechanism
219 of Cia secretion [41]. Further investigations into CiaB suggested that this protein may be
220 essential for cell invasion, as three mutants with insertional disruptions of the *ciaB* gene
221 exhibited a significant reduction in internalization in host cells [42]. Interestingly, Cia protein
222 synthesis was found to be enhanced in the presence of deoxycholate bile acid, but Cia
223 secretion was unchanged. This finding suggests that production of Cia proteins may occur
224 early in the colonization process, but secretion is only initiated once the bacterium has
225 adhered to its long-term colonization site [41].

226 In addition to their roles in adhesion, some flagellins and flagellar components also
227 contribute to epithelial cell invasion by *C. jejuni*. In studies of mutant strains, Grant *et al.*
228 demonstrated that flagella are important for *C. jejuni*'s internalization in epithelial cells [18].
229 Notably, the protein FlaC, which, like Cia proteins, is secreted by the flagellar apparatus, has
230 been shown to be required for invasion [38]. Similarly, the Δ *motAB* mutant strain, lacking the
231 genes encoding the flagellar motor, demonstrated a significant decrease in cell invasion
232 capacity [43].

233 Finally, some lysophospholipids contained in the membrane of *C. jejuni* are also
234 considered to be novel virulence factors. Short lysophosphatidylethanolamines (lysoPE) were
235 reported to permeabilize host cell membranes and thus cause cell damage via oxidative stress
236 [44].

237

238 **2.3. Toxin production and pro-inflammatory factors**

239 After *C. jejuni* interacts with epithelial cells, it releases a holotoxin – cytolethal distending toxin
240 (CDT) – that may be responsible for the cytopathic effects of *C. jejuni* infection. CDT belongs
241 to a family of bacterial toxins that affect the epithelial cell layer and interrupt the cell division
242 process, leading to cell death [45]. This toxin is produced by a wide range of pathogenic Gram-
243 negative bacteria including *Escherichia coli*, *Helicobacter* spp., and other species of
244 *Campylobacter*. The CDT of *C. jejuni* belongs to the AB family of toxins, which feature an active
245 subunit (CdtB) and two binding subunits (CdtA and CdtC) encoded by the *cdtA*, *cdtB*, and *cdtC*
246 genes located in the same operon [46].

247 The subunits CdtA and CdtC are thought to enable the binding of CDT to epithelial cells by
248 attaching themselves to the cholesterol-rich lipid rafts of the cell membrane, thus facilitating
249 the entry of CdtB into the cell cytoplasm. CdtB is now known to be the toxic component, as a
250 microinjection or transfection of only this subunit into host cells causes the same cell cycle
251 arrest observed with the complete CDT toxin. Once in the cell, CdtB reaches the cell nucleus
252 and causes DNA damage (double-strand breaks). CdtB is thought to act as a deoxyribonuclease
253 I, as it shares structural similarity with DNase I-like proteins [47]. Host cells react to this DNA
254 damage by initiating a regulatory cascade that includes phosphorylation of the histone protein
255 H2AX, leading to the recruitment of Rad50, a DNA-repair protein for double-strand breaks
256 [48]. This process blocks the cell cycle at the G2/M interphase to allow for DNA repair. If the
257 damage is too extensive, repair fails and the cell cycle arrest leads to cellular distention,
258 senescence, and finally cell death [49].

259 The CDT toxin has been reported to provoke autophagy and apoptosis in vitro and
260 inflammation in vivo, along with cell senescence. A recent study in colonic epithelial cells
261 highlighted CDT-induced pyroptosis, a process of pro-inflammatory programmed cell death
262 characterized by the emergence of large bubbles from the plasma membrane, which leads to

263 cell membrane rupture and eventually the release of cell content. This form of programmed
264 cell death was originally known to be triggered by pro-inflammatory caspases but it now
265 appears that it can also be mediated by virulence factors [50]. Specifically, Gu *et al.*
266 demonstrated the induction of gasdermin E-mediated pyroptosis in response to the CDT of *C.*
267 *jejuni*. After CDT exposure, there was a considerable elevation in ROS levels in epithelial cells,
268 initiating the caspase-9/caspase-3/gasdermin E pyroptosis pathway [50]. In addition to this
269 toxin-induced inflammation, some virulence factors cause damage to the intestine by
270 triggering inflammatory responses. For example, the lipoprotein JlpA activates NF-KB and p38
271 MAP kinase pathways in Hep-2 cells [51].

272 **2.4. Survival**

273 During commensal carriage in food animals, *C. jejuni* must cope with various stresses related
274 to oxygen levels, desiccation, disinfectants, or temperature shocks. In these environments, *C.*
275 *jejuni* may also encounter bile salts, antibiotics, and defenses of the host immune system.
276 Resistance to many drugs and bile salts is often mediated by the interaction between two
277 *Campylobacter* multidrug efflux pumps (CME), encoded by the *cmeABC* operon and the
278 *cmeDEF* operon [52–54]. To protect itself from disinfection protocols, dessication, and high
279 oxygen levels, *C. jejuni* is able to form biofilms [55]. In addition, this bacterium is able to enter
280 a viable-but-not-culturable (VBNC) state in response to osmotic and temperature shocks, pH
281 modification, or nutrient starvation [56]. A final form of defense are capsular polysaccharides
282 (CPS) that coat *C. jejuni* cells, which are involved in cell wall maintenance but have also been
283 implicated in evasion from the host immune system [57].

284

285 **3. Extracellular vesicles in Gram-negative bacteria and *C. jejuni***


286 **3.1. Secretion of extracellular vesicles in Gram-negative bacteria**

287 Bacteria constitutively release extracellular vesicles, termed bacterial extracellular vesicles
288 (BEVs), which vary in their composition, size, content, and architecture depending on the
289 biogenesis route, growth phase, and environmental conditions present (e.g., pH, temperature,
290 nutrient content, ionic force, antibiotic pressure, or oxygen stress). The liberation of
291 membrane vesicles from Gram-negative bacteria is thought to be an alternative secretion
292 system that facilitates both interbacterial and bacterial-host cargo transfer. Indeed, vesicles
293 from Gram-negative bacteria were shown to integrate into the membranes of foreign
294 bacteria, both Gram-positive and Gram-negative [58]. Vesicles may also adhere to or integrate
295 into eukaryotic cells, promoting adherence of the parent bacterium to host cells. There is an
296 increasing body of evidence that BEVs are the cause of numerous pathologies, through either
297 bacterial-bacterial or bacterial-host interactions [59,60]. Nanosized BEVs are released in both
298 favorable and unfavorable physiological conditions as a mechanism for cell-free intracellular
299 communication.

300 Through their roles in bacterial short- and long-distance communication, stress
301 response, detoxification, lateral gene transfer, and intracellular competition, BEVs allow
302 bacteria to interact rapidly and adapt to their environments, and thus to cause various
303 pathologies [61]. In particular, BEVs have a direct impact on pathogenesis by delivering toxins
304 and other virulence factors to the host during infection [62]. Indeed, in *C. jejuni*, the well-
305 characterized toxin CDT is secreted in its active form via BEVs [63]. Bacterial vesicles may
306 internalize into epithelial or immune cells or fuse with eukaryotic membranes to release their
307 cargo inside the cytoplasm. In addition to toxin delivery, BEVs enable long-distance delivery
308 of virulence factors such as adhesins, colonization factors, outer membrane proteins, LPSs,
309 flagellins, and proteases [64]. BEVs are particularly suitable for delivering insoluble proteins
310 and proteins lacking signal peptides. Additionally, by densely packaging virulence factors, BEVs

311 increase their stability and concentration until delivery to the target. They also provide a
312 protective barrier, safeguarding their contents against degradation by host proteases or
313 nucleases, or low/high concentrations of salt or cations. Compared to classical secretion
314 systems that export individual virulence factors, BEVs may enhance pathogenesis through the
315 coordinated delivery of multiple, densely packed factors.

316 BEVs can be easily observed in bacterial preparations by electron microscopy. They
317 may be formed from cellular debris during cell lysis (Fig. 3a), but can also be generated through
318 bacterial metabolic activities. The generation of extracellular vesicles under non-lytic
319 conditions is beneficial for bacteria by eliminating misfolded proteins and relieving membrane
320 stress. In this process, the outer membrane swells to form outer membrane vesicles (OMVs)
321 that are then released in the medium (Fig. 3b). The resulting liberated spherical particles,
322 ranging in diameter from 10 to 500 nm, consist mainly of periplasmic proteins and envelope
323 components such as phospholipids, lipoproteins, LPSs, lipooligosaccharides (LOS), and outer
324 membrane proteins (Fig. 3e). Moreover, Gram-negative bacteria may produce double-
325 membrane bilayer vesicles via the protrusion of both the outer and cytoplasmic membrane
326 (Fig. 3c). These so-called outer-inner membrane vesicles (O-IMVs) are believed to carry
327 bacterial cytoplasmic content, e.g., proteins, ATP, nucleic acids, effectors, and quorum-
328 sensing molecules (Fig. 3c and f) [65]. Several Gram-negative bacteria have also been shown
329 to liberate nanosized filaments attached to OMVs [59,66]. When a nanofilament forms as a
330 continuous tubular structure that resembles multiple OMVs, it is called a nanotube (Fig. 3d);
331 when the nanofilament is instead attached to a single OMV, it is called a nanopod. Nanotubes
332 and nanopods may bridge different cells together and facilitate their communication via
333 OMVs.




334

335 **Figure 3. Diverse mechanisms of bacterial extracellular vesicle (BEV) secretion and content**
 336 **of the resulting vesicles. (a)** OMVs can be formed by a bleb of the outer membrane or **(b)**
 337 during cell lysis. **(c)** BEVs may also be formed by a protrusion of both the inner and outer
 338 membranes, forming O-IMVs. **(d)** BEVs can be secreted in a nanofilament containing one
 339 vesicle (nanopods) or several (nanotubes). **(e-f)** These different mechanisms result in
 340 differences in the contents of secreted vesicles.

341

342 *C. jejuni* cells, which are approximately 1–4 μm long, can liberate vesicles of diameters
 343 reaching 300–500 nm (Fig. 4). The biogenesis and liberation of BEVs of this size represent a
 344 huge loss of both membrane and energy. This strongly suggests that BEVs have vital roles in
 345 the maintenance of normal bacterial physiological activities. Campylobacters have been
 346 observed to produce BEVs both in the presence and absence of stress. To date, though, no
 347 model has been proposed for BEV biogenesis in *Campylobacter*, and the mechanisms
 348 described in other Gram-negative bacteria appear to be species-specific. For instance,
 349 *Pseudomonas aeruginosa*, which has a highly fluid membrane, can produce BEVs only when
 350 outer membrane fluidity is reduced, which occurs in response to the interaction between the
 351 quorum-sensing pseudomonas quinolone signal (PQS) molecule and lipid A protein [67]. Once

352 the outer membrane is stabilized, the membrane curvature enables formation of BEVs.
353 Another mechanism, proposed for *Salmonella*, involves modifications in the connections
354 between the cell wall and the outer membrane that allow blebbing [68]. This mechanism is
355 supported by the observation that BEVs are released with high frequency at cell division sites.
356 Nevertheless, this model cannot be considered universal because BEVs can also be released
357 from other cell sites. Finally, bacteria whose flagellum is sheathed with LPS, such as *Vibrio*
358 *fischeri* or *Vibrio cholerae*, have been shown to release BEVs via flagellar rotation [69].



359
360 **Figure 4. Scanning electron microscopy image of *Campylobacter jejuni* and its purified**
361 **extracellular vesicles. (a) *C. jejuni* on a BHI plate. Its S-shaped morphology, polar flagella, and**
362 **extracellular vesicles (yellow arrows) can be observed. (b) Extracellular vesicles secreted by *C.***
363 ***jejuni* are heterogenous in size, ranging in diameter from around 20 nm to 300 nm. Scale bars**
364 **= 500 nm.**

365
366 One model that may be more generally applicable is that proposed by Roier *et al.* based
367 on the maintenance of lipid asymmetry (MLA) pathway [70]. This pathway is highly conserved
368 in Gram-negative bacteria and is involved in the retrograde trafficking of phospholipids from
369 the outer leaflet of the outer membrane to the inner membrane. When this retrograde
370 trafficking is blocked or down-regulated, the accumulation of phospholipids in the outer
371 leaflet of the outer membrane leads to an asymmetric expansion and the formation of BEVs.

372 The role of this pathway in BEV production in *C. jejuni* was confirmed by Davies *et al.* [71].
373 Using the bile salt sodium taurocholate as a potential regulator, they observed that *C. jejuni*
374 regulated BEV production through the MLA pathway without compromising membrane
375 stability. In the presence of sodium taurocholate, BEV production was enhanced in the wild-
376 type strain but not in an *miaA* mutant that lacked the outer membrane component of the MLA
377 pathway. This work suggests that *C. jejuni* is able to produce BEVs of different sizes, numbers,
378 and cargos depending on signals from the host gut, and moreover, that such environmental
379 signals may be responsible for triggering different mechanisms for BEV biogenesis.

380

381 **3.2. Implication of BEVs in *C. jejuni* virulence**

382 In contrast to archetypal Gram-negative bacteria, which have six secretion systems for
383 exporting molecules (Type I to Type VI, T1SS-T6SS), genetic analyses of *Campylobacter* isolates
384 suggest that this bacterium does not possess type I, type IV or type V secretion system and
385 only a few genes encoding protein components of type II secretion system have been
386 identified. Thus, *C. jejuni* may rely only on Type III and VI secretion systems to export biological
387 macromolecules [72]. Unlike the majority of Gram-negative pathogenic bacteria that possess
388 a dedicated T3SS (e. g. *Salmonella*), *C. jejuni* has no dedicated T3SS. Instead, its flagellum holds
389 a dual role of motility and protein export [72]. It transports not only flagellar proteins such as
390 flagellin and allied proteins, but also releases some non-flagellar virulence factors such as the
391 invasion antigen Cia proteins and FlaC, which plays a role in cell adhesion and invasion [38].
392 Concerning the type IV secretion system, the 54,065 genomes of *C. jejuni* and *C. coli* from the
393 PubMLST database were screened and only 7 genes associated with T4SS were identified, with
394 the majority encoded in plasmids pVir and pTet [72]. This result suggests that most of
395 *Campylobacter* isolates do not produce a T4SS. Finally, in 2012, a study showed that some *C.*

396 *jejuni* isolates encode a T6SS involved in bile salt survival, adhesion to host cells and invasion
397 [73]. More recent studies tried to evaluate the percentage of *C. jejuni* isolates encoding a
398 functional T6SS but the results vary a lot (between 27 to 74% of clinical isolates were positive).
399 [72]. A more detailed analysis is needed to elucidate whether the T6SS is functional in *C. jejuni*.

400 Due to the absence of some prototypical secretion systems (type I, II, V and often type
401 IV), campylobacters must use alternative mechanisms to secrete virulence factors in host cells
402 and so exert their pathogenic effects. Like other Gram-negative bacteria, campylobacters
403 seem to rely on extracellular vesicles to transport virulence factors. As mucosal pathogens,
404 campylobacters use BEVs to coordinate the secretion of major virulence factors (active
405 proteins, nucleic acids, metabolites, peptidoglycan fragments) and to deliver them in the
406 cytoplasm of host cells rather than in the surrounding medium. Indeed, it has been
407 demonstrated that *C. jejuni* uses BEVs to deliver toxins [63] and certain proteins that promote
408 adhesion and invasion of host cells [74]. BEVs carrying CDT have been shown to directly
409 damage cellular DNA and induce apoptosis in a range of mammalian cell lines [75]. Recently,
410 it was shown that CDT is mainly located in EVs and induces epithelial cell distension, even in
411 absence of surface proteins. Interestingly, this study elucidated partially the mechanism of EV
412 uptake in *C. jejuni* by showing that EVs binds preferentially to complex glycans of host cells
413 (e.g. Lewis antigens, blood group A antigens, gangliosides) [76]. Furthermore, the addition of
414 isolated BEVs was found to improve the adhesion and internalization of *C. jejuni* to intestinal
415 epithelial cells, confirming the importance of BEVs in establishing infection [77,78].

416 A few studies have attempted to characterize the proteinaceous cargo of the BEVs
417 secreted by *C. jejuni* under different conditions. Vesicles have been reported to contain
418 numerous and diverse proteins described or predicted as virulence factors with a role in the
419 pathogenesis of *C. jejuni* (Table 1). First among these are the flagellar proteins (flagellins FlaA,

420 FlaB, FlaC, and FlaD, and flagellar hook proteins FlaE, FlgE, FlgK, FlgL, FlgP, and FliD), which
421 have been found in BEVs secreted by different strains of *C. jejuni* (81-716 and 11168) and at
422 different growing temperatures (37°C and 42°C)[79–82]. As mentioned earlier, these proteins,
423 which form components of the flagellum, are considered virulence factors of pathogenic
424 bacteria because of the importance of the flagellum in motility, adhesion, and stimulation of
425 the host immune system [83–85]. Many different adhesins have also been found in vesicles,
426 notably the fibronectin binding proteins FlpA and CadF, the lipoproteins RlpA and JlpA, and
427 the capsule polysaccharide export protein KpsD [74,79–81]. In addition, vesicles have been
428 found to contain three outer membrane proteins identified as virulence factors: the Omp18
429 protein, implicated in adhesion and immune system stimulation; the ChuA heme receptor
430 protein, involved in adhesion and invasion of host cells; and the major outer membrane
431 protein (MOMP) PorA, which plays a role in the adhesion of *C. jejuni* to intestinal cells [81]. An
432 analysis of the content of vesicles from strain 81-176 detected a chemoreceptor protein, CheV
433 [80], which is involved in chemotaxis, driving the directional changes during swimming to
434 allow bacteria to reach target cells, and is thus implicated in the first step of pathogenesis.
435 Vesicles secreted by *C. jejuni* strain 81-176 were also found to contain the molecular
436 chaperone GroEL, which has multiple roles in pathogenesis, namely adhesion, invasion, and
437 immune system stimulation. BEVs from strains 81-187 and 11168 have been reported to
438 contain several antigens, for example the well-known Peb antigens (Peb1A, 2, 3 and 4), which
439 play roles in adhesion, invasion, and survival, and CjaA and CjaC, which promote inflammation
440 [62],[65-67]. The immunogenic CjaA is loosely connected with the inner membrane, but it can
441 be transported to the cell surface and is present in EVs [86].
442 The serine protease HtrA—responsible for the disruption of tight and adherens junctions
443 during invasion—was identified in the BEV content of strains 81-176, 11168, and 11168H. In

444 addition, studies highlighted the proteolytic activity of *C. jejuni* BEVs and identified several
 445 proteases implicated in this process. Elmi *et al.* showed that the proteases HtrA and Cj1365c
 446 contained in the *C. jejuni* BEVs contributed to the cleavage of E-cadherin and occludin,
 447 resulting in the disruption of adherens and tight junctions, respectively [78]. This cleavage of
 448 tight and adherens junctions induced by BEVs was shown to be enhanced when bile salt
 449 sodium taurocholate was added to the medium [87].

450 Interestingly, vesicles also contained some components of efflux pumps, like CmeA and CmeC,
 451 which have been implicated in antibiotic resistance and survival [80,81]. Finally, several
 452 studies have reported the presence of the CDT subunits CdtA, CdtB, and CdtC in vesicles
 453 secreted by different strains of *C. jejuni*. In brief, proteomic analyses of BEV content have
 454 confirmed that numerous virulence factors, representing all steps of *C. jejuni* pathogenesis,
 455 are packed into these vesicles [63,74].

456

Virulence factor	Type	Role	Step of pathogenesis concerned	Reference
FlaA and FlaB	Flagellins	Corkscrew motility, immune stimulating	Reaching target cells Adhesion Invasion	[79–81]
FlaC	Flagellins			[81]
FlaD	Putative flagellin			[79]
FlaE and FlgP	Flagellar hook proteins			[81]
FlgL, FlgE and FlgC				[81,82]
FliD and FlgK	Flagellar hook proteins			[79]
CadF	Fibronectin binding protein	Adhesin	Adhesion	[74,79–81]
FlpA		Adhesin	Adhesion	[74]
RlpA	Lipoprotein	Cell wall biogenesis	Adhesion	[81]
JlpA	Surface-exposed lipoprotein	Adhesin	Adhesion	[80]
Omp18	Outer membrane protein	Immune system stimulation	Adhesion Cell damage (via inflammation)	[81]

PorA	MOMP	Ion transport (porin) and adhesion to fibronectin	Adhesion and cell damage (porin)	[79,81]
KpsD	Capsule polysaccharide export protein	Capsule biosynthesis	Adhesion	[79,81]
ChuA	Outer membrane haem receptor protein	TonB-dependent heme receptor	Adhesion Invasion	[80,81]
GroEL	Molecular chaperone	Adhesion Immune system stimulation	Adhesion Cell damage (via inflammation)	[81]
CheV	Chemoreceptor protein	Chemotaxis	Reaching target cells	[80]
CjaA, CjaC	<i>C. jejuni</i> antigens	Immune system stimulation	Cell damage (via inflammation)	[79–81]
Peb1A, 2, 3	Major antigen protein	Biofilm formation, motility, host cell invasion	Adhesion Invasion Survival	[80,81]
Peb4				[74,81]
HtrA	Serine proteases and chaperone	Folding of adhesins Disruption of tight and adherens junctions	Adhesion Invasion	[74,79,80]
CmeA and CmeC	Efflux pump subunits	Resistance to broad range of antimicrobial	Survival	[80,81]
CdtA, CdtB and CdtC	Cytolethal distending toxin subunits	DNase like protein toxin making double DNA break in host cells	Cell damage (via DNA damage)	[63,74,81]

457 **Table 1. Virulence factors of *Campylobacter jejuni* found in the proteinaceous cargo of**
458 **bacterial extracellular vesicles (BEVs) by proteomic studies and the contribution of these**
459 **factors to the pathogenic process.** MOMP = major outer membrane protein

460

461 Recently, Khan *et al.* demonstrated that BEVs of *C. jejuni* with different cargos and
462 morphological attributes induced different, biologically relevant host responses [88]. Using
463 FRET and fluorescence dye dequenching assays, they showed *C. jejuni* BEVs are fusogenic and
464 specialized for transporting macromolecules. They reported that host cell-specific differences
465 in BEV uptake from the extracellular medium were mediated by heterogeneity in vesicles
466 caused by underlying differences in the membrane phospholipids acquired from the source
467 bacteria and the abundance of surface proteins. Furthermore, when human and avian cells

468 were compared as host models, the uptake of different OMVs was observed to vary
469 preferentially among different target cells. However, the intracellular accumulation of BEVs
470 was concentration-dependent in both cell lines. Using pharmacological inhibitors, this study
471 pointed that although the dynamin-dependent pathway was predominant in BEV uptake for
472 both cell types, the actin filament-dependent micropinocytosis was involved in BEV
473 internalization in avian cells [88]. All together, these data suggest that better characterization
474 of individual BEVs may shed light on their complex roles in bacterial infections.

475 With respect to BEV characterization, it is interesting to note that *C. fetus* releases BEVs
476 with a distinctive S-layer on the surface [89]. This S-layer is a bidimensional crystalline
477 structure formed by various surface-layer proteins, which mediates the evasion of the
478 immune response and is involved in cell adhesion. Moreover, the S-layer serves as a means of
479 protection from external stress for the bacterium. BEVs coated with an S-layer are probably
480 more resistant to adverse environmental conditions, which may prolong the life of the
481 released vesicles. It remains to be seen whether other *Campylobacter* species also produce
482 BEVs enveloped with an S-layer.

483

484 **4. Conclusion**

485 Despite the large amount of energy resources required, the non-lytic production of BEVs
486 throughout the life of a bacterium is evolutionarily conserved in both Gram-negative and
487 Gram-positive species. In Gram-negative bacteria, BEVs can be released from different cellular
488 locations and, due to the protection provided by the lipid bilayer, enable the transportation
489 of various molecules in their active forms. BEVs are involved in many cellular functions,
490 including mediating bacterial adaptation to various environments, facilitating intercellular
491 communication, delivering virulence factors, or transferring DNA.

492 In *C. jejuni*, BEVs are associated with the maintenance of virulence, stress response,
493 improvements in cell adherence, colonization in different hosts, and responses to signals from
494 the host gut and microbiota. The lipid bilayer protects transported molecules from host
495 proteases and immune cells and delivers molecules directly to or near their target.
496 Additionally, vesicles can play a significant role in bacterial communication by transporting
497 molecules between cells.

498 Although many studies have reported on the biogenesis and function of bacterial
499 extracellular vesicles, the formation and role of BEVs in campylobacters merit further
500 investigation. Depending on the environmental signals present, temperature, or the identity
501 of the host (avian or human cells), *C. jejuni* releases BEVs of various sizes, charges, and cargos,
502 but the reasons and mechanisms underlying these differences remain unclear. New analytical
503 methods are needed to distinguish the variety of regulatory roles these structures play during
504 pathogenesis. In particular, imaging techniques that enable dynamic monitoring are sorely
505 needed for investigations of the biogenesis and fate of BEVs. Additionally, further research is
506 required into the mechanisms by which BEV content and function adapt to the external
507 environment of the bacterium; such knowledge will help to elucidate the specific functions of
508 BEVs in pathogenesis. Understanding BEVs biogenesis, cargo and uptake into host cells can
509 also be crucial for the development of BEVs-based vaccines to prevent *C. jejuni* infections in
510 humans, as has been tested for chickens [90]. Based on proteomic studies, it is clear that BEVs
511 transport a high diversity of virulence factors with roles in all steps of infection, plainly
512 demonstrating that BEV secretion is a key mechanism for *C. jejuni* virulence. Identification of
513 the factors that influence the production and composition of BEVs in the gut will be key in
514 improving our understanding of both *Campylobacter* physiology and the functioning of
515 holobionts.

516

517 **Declaration of competing interest**

518 The authors have no conflicts of interest to declare.

519

520 **Acknowledgments**

521 This work was supported by an ANR grant (Project ANR-21-CE42-0008 ELISE) and the INRAE's
522 department MICA (Project Vélib). We thank Thierry Meylheuc and Christine Longin for their
523 expertise and the MIMA2 platform for access to electron microscopy equipment (MIMA2,
524 INRAE, 2018. Microscopy and Imaging Facility for Microbes, Animals and Foods,
525 <https://doi.org/10.15454/1.5572348210007727E12>).

526

527 **References**

- 528 1. Lopes GV, Ramires T, Kleinubing NR, Scheik LK, Fiorentini ÂM, Padilha da Silva W. Virulence
529 factors of foodborne pathogen *Campylobacter jejuni*. *Microb Pathog.* déc 2021;161(Pt
530 A):105265.
- 531 2. *Campylobacter* - Key facts [Internet]. World Health Organization. 2020 [cité 5 févr 2024].
532 Disponible sur: <https://www.who.int/news-room/fact-sheets/detail/Campylobacter>
- 533 3. Centers for Disease Control and Prevention (U.S.). Antibiotic resistance threats in the United
534 States, 2019 [Internet]. Centers for Disease Control and Prevention (U.S.); 2019 nov [cité 16 août
535 2022]. Disponible sur: <https://stacks.cdc.gov/view/cdc/82532>
- 536 4. European Food Safety Authority, European Centre for Disease Prevention and Control. The
537 European Union One Health 2022 Zoonoses Report. *EFSA Journal.* 2023;21(12):222.
- 538 5. The European Union summary report on trends and sources of zoonoses, zoonotic agents and
539 food-borne outbreaks in 2016. *EFSA J.* 12 déc 2017;15(12):e05077.
- 540 6. Batz MB, Hoffmann S, Morris JG. Ranking the disease burden of 14 pathogens in food sources in
541 the United States using attribution data from outbreak investigations and expert elicitation. *J*
542 *Food Prot.* juill 2012;75(7):1278-91.
- 543 7. Hansson I, Sandberg M, Habib I, Lowman R, Engvall EO. Knowledge gaps in control of
544 *Campylobacter* for prevention of campylobacteriosis. *Transbound Emerg Dis.* mai 2018;65 Suppl
545 1:30-48.
- 546 8. Vandamme P, De Ley J. Proposal for a New Family, *Campylobacteraceae*. *International Journal of*
547 *Systematic and Evolutionary Microbiology.* 1991;41(3):451-5.
- 548 9. Morcrette H, Kovacs-Simon A, Tennant RK, Love J, Wagley S, Yang ZR, et al. *Campylobacter jejuni*
549 11168H Exposed to Penicillin Forms Persister Cells and Cells With Altered Redox Protein Activity.
550 *Front Cell Infect Microbiol.* 2020;10:565975.
- 551 10. Young KT, Davis LM, Dirita VJ. *Campylobacter jejuni*: molecular biology and pathogenesis. *Nat*
552 *Rev Microbiol.* sept 2007;5(9):665-79.
- 553 11. European Food Safety Authority, European Centre for Disease Prevention and Control. The
554 European Union One Health 2020 Zoonoses Report. *EFSA Journal.* 2021;20(12):e06971.
- 555 12. Black RE, Levine MM, Clements ML, Hughes TP, Blaser MJ. Experimental *Campylobacter jejuni*
556 infection in humans. *J Infect Dis.* mars 1988;157(3):472-9.
- 557 13. Nachamkin I, Allos BM, Ho T. *Campylobacter* species and Guillain-Barré syndrome. *Clin Microbiol*
558 *Rev.* juill 1998;11(3):555-67.
- 559 14. Allos BM. *Campylobacter jejuni* Infections: update on emerging issues and trends. *Clin Infect Dis.*
560 15 avr 2001;32(8):1201-6.
- 561 15. Shigematsu M, Umeda A, Fujimoto S, Amako K. Spirochaete-like swimming mode of
562 *Campylobacter jejuni* in a viscous environment. *Journal of Medical Microbiology.* 1 juin
563 1998;47(6):521-6.

- 564 16. Ferrero RL, Lee A. Motility of *Campylobacter jejuni* in a viscous environment: comparison with
565 conventional rod-shaped bacteria. *J Gen Microbiol.* janv 1988;134(1):53-9.
- 566 17. Svensson SL, Pryjma M, Gaynor EC. Flagella-mediated adhesion and extracellular DNA release
567 contribute to biofilm formation and stress tolerance of *Campylobacter jejuni*. *PLoS One.*
568 2014;9(8):e106063.
- 569 18. Grant CC, Konkel ME, Cieplak W, Tompkins LS. Role of flagella in adherence, internalization, and
570 translocation of *Campylobacter jejuni* in nonpolarized and polarized epithelial cell cultures. *Infect*
571 *Immun.* mai 1993;61(5):1764-71.
- 572 19. Diepold A, Armitage JP. Type III secretion systems: the bacterial flagellum and the injectisome.
573 *Philos Trans R Soc Lond B Biol Sci.* 5 oct 2015;370(1679):20150020.
- 574 20. Yeh HY, Hiatt KL, Line JE, Seal BS. Characterization and antigenicity of recombinant
575 *Campylobacter jejuni* flagellar capping protein FljD. *J Med Microbiol.* avr 2014;63(Pt 4):602-9.
- 576 21. Sourjik V, Wingreen NS. Responding to chemical gradients: bacterial chemotaxis. *Curr Opin Cell*
577 *Biol.* avr 2012;24(2):262-8.
- 578 22. Mund NLA, Masanta WO, Goldschmidt AM, Lugert R, Groß U, Zautner AE. Association of
579 *Campylobacter Jejuni* ssp. *Jejuni* Chemotaxis Receptor Genes with Multilocus Sequence Types
580 and Source of Isolation. *Eur J Microbiol Immunol (Bp).* 19 juill 2016;6(3):162-77.
- 581 23. Marchant J, Wren B, Ketley J. Exploiting genome sequence: predictions for mechanisms of
582 *Campylobacter* chemotaxis. *Trends Microbiol.* avr 2002;10(4):155-9.
- 583 24. Clark C, Berry C, Demczuk W. Diversity of transducer-like proteins (Tlps) in *Campylobacter*. *PLoS*
584 *One.* 2019;14(3):e0214228.
- 585 25. Yao R, Burr DH, Guerry P. CheY-mediated modulation of *Campylobacter jejuni* virulence. *Mol*
586 *Microbiol.* mars 1997;23(5):1021-31.
- 587 26. Backert S, Boehm M, Wessler S, Tegtmeyer N. Transmigration route of *Campylobacter jejuni*
588 across polarized intestinal epithelial cells: paracellular, transcellular or both? *Cell Communication*
589 *and Signaling.* 30 sept 2013;11(1):72.
- 590 27. Brás AM, Ketley JM. Transcellular translocation of *Campylobacter jejuni* across human polarised
591 epithelial monolayers. *FEMS Microbiol Lett.* 15 oct 1999;179(2):209-15.
- 592 28. Sharafutdinov I, Esmaeili DS, Harrer A, Tegtmeyer N, Sticht H, Backert S. *Campylobacter jejuni*
593 Serine Protease HtrA Cleaves the Tight Junction Component Claudin-8. *Front Cell Infect*
594 *Microbiol.* 2020;10:590186.
- 595 29. Monteville MR, Konkel ME. Fibronectin-Facilitated Invasion of T84 Eukaryotic Cells by
596 *Campylobacter jejuni* Occurs Preferentially at the Basolateral Cell Surface. *Infect Immun.* déc
597 2002;70(12):6665-71.
- 598 30. Boehm M, Hoy B, Rohde M, Tegtmeyer N, Bæk KT, Oyarzabal OA, et al. Rapid paracellular
599 transmigration of *Campylobacter jejuni* across polarized epithelial cells without affecting TER:
600 role of proteolytic-active HtrA cleaving E-cadherin but not fibronectin. *Gut Pathog.* 25 avr
601 2012;4:3.

- 602 31. Moser I, Schroeder W, Salnikow J. *Campylobacter jejuni* major outer membrane protein and a
603 59-kDa protein are involved in binding to fibronectin and INT 407 cell membranes. *FEMS*
604 *Microbiol Lett.* 15 déc 1997;157(2):233-8.
- 605 32. Konkel ME, Garvis SG, Tipton SL, Anderson DE, Cieplak W. Identification and molecular cloning of
606 a gene encoding a fibronectin-binding protein (CadF) from *Campylobacter jejuni*. *Mol Microbiol.*
607 *juin 1997;24(5):953-63.*
- 608 33. Larson CL, Samuelson DR, Eucker TP, O'Loughlin JL, Konkel ME. The fibronectin-binding motif
609 within FlpA facilitates *Campylobacter jejuni* adherence to host cell and activation of host cell
610 signaling. *Emerg Microbes Infect.* oct 2013;2(10):e65.
- 611 34. Talukdar PK, Negretti NM, Turner KL, Konkel ME. Molecular Dissection of the *Campylobacter*
612 *jejuni* CadF and FlpA Virulence Proteins in Binding to Host Cell Fibronectin. *Microorganisms.* 11
613 mars 2020;8(3):389.
- 614 35. Bæk KT, Vegge CS, Brøndsted L. HtrA chaperone activity contributes to host cell binding in
615 *Campylobacter jejuni*. *Gut Pathog.* déc 2011;3(1):13.
- 616 36. Pei Z, Burucoa C, Grignon B, Baqar S, Huang XZ, Kopecko DJ, et al. Mutation in the *peb1A* locus
617 of *Campylobacter jejuni* reduces interactions with epithelial cells and intestinal colonization of
618 mice. *Infect Immun.* mars 1998;66(3):938-43.
- 619 37. Ashgar SSA, Oldfield NJ, Wooldridge KG, Jones MA, Irving GJ, Turner DPJ, et al. CapA, an
620 Autotransporter Protein of *Campylobacter jejuni*, Mediates Association with Human Epithelial
621 Cells and Colonization of the Chicken Gut. *J Bacteriol.* mars 2007;189(5):1856-65.
- 622 38. Song YC, Jin S, Louie H, Ng D, Lau R, Zhang Y, et al. FlaC, a protein of *Campylobacter jejuni*
623 TGH9011 (ATCC43431) secreted through the flagellar apparatus, binds epithelial cells and
624 influences cell invasion. *Mol Microbiol.* juill 2004;53(2):541-53.
- 625 39. Bacon DJ, Alm RA, Burr DH, Hu L, Kopecko DJ, Ewing CP, et al. Involvement of a plasmid in
626 virulence of *Campylobacter jejuni* 81-176. *Infect Immun.* août 2000;68(8):4384-90.
- 627 40. Holden KM, Gilbert M, Coloe PJ, Li J, Fry BN. The role of WlaRG, WlaTB and WlaTC in
628 lipooligosaccharide synthesis by *Campylobacter jejuni* strain 81116. *Microbial Pathogenesis.* juin
629 2012;52(6):344-52.
- 630 41. Rivera-Amill V, Kim BJ, Seshu J, Konkel ME. Secretion of the virulence-associated *Campylobacter*
631 invasion antigens from *Campylobacter jejuni* requires a stimulatory signal. *J Infect Dis.* 1 juin
632 2001;183(11):1607-16.
- 633 42. Konkel ME, Kim BJ, Rivera-Amill V, Garvis SG. Bacterial secreted proteins are required for the
634 internalization of *Campylobacter jejuni* into cultured mammalian cells. *Molecular Microbiology.*
635 1999;32(4):691-701.
- 636 43. Mertins S, Allan BJ, Townsend HG, Köster W, Potter AA. Role of *motAB* in adherence and
637 internalization in polarized Caco-2 cells and in cecal colonization of *Campylobacter jejuni*. *Avian*
638 *Dis.* mars 2013;57(1):116-22.
- 639 44. Cao X, van de Lest CHA, Huang LZ, van Putten JPM, Wösten MMSM. *Campylobacter jejuni*
640 permeabilizes the host cell membrane by short chain lysophosphatidylethanolamines. *Gut*
641 *Microbes.* 2022;14(1):2091371.

- 642 45. Johnson WM, Lior H. A new heat-labile cytolethal distending toxin (CLDT) produced by
643 *Campylobacter* spp. *Microb Pathog.* févr 1988;4(2):115-26.
- 644 46. Pickett CL, Pesci EC, Cottle DL, Russell G, Erdem AN, Zeytin H. Prevalence of cytolethal distending
645 toxin production in *Campylobacter jejuni* and relatedness of *Campylobacter* sp. *cdtB* gene. *Infect*
646 *Immun.* juin 1996;64(6):2070-8.
- 647 47. Lara-Tejero M, Galán JE. A bacterial toxin that controls cell cycle progression as a
648 deoxyribonuclease I-like protein. *Science.* 13 oct 2000;290(5490):354-7.
- 649 48. Hassane DC, Lee RB, Pickett CL. *Campylobacter jejuni* cytolethal distending toxin promotes DNA
650 repair responses in normal human cells. *Infect Immun.* janv 2003;71(1):541-5.
- 651 49. Whitehouse CA, Balbo PB, Pesci EC, Cottle DL, Mirabito PM, Pickett CL. *Campylobacter jejuni*
652 cytolethal distending toxin causes a G2-phase cell cycle block. *Infect Immun.* mai
653 1998;66(5):1934-40.
- 654 50. Gu J, Lin Y, Wang Z, Pan Q, Cai G, He Q, et al. *Campylobacter jejuni* Cytolethal Distending Toxin
655 Induces GSDME-Dependent Pyroptosis in Colonic Epithelial Cells. *Front Cell Infect Microbiol.*
656 2022;12:853204.
- 657 51. Jin S, Song YC, Emili A, Sherman PM, Chan VL. JlpA of *Campylobacter jejuni* interacts with surface-
658 exposed heat shock protein 90 α and triggers signalling pathways leading to the activation of NF-
659 κ B and p38 MAP kinase in epithelial cells. *Cellular Microbiology.* 2003;5(3):165-74.
- 660 52. Lin J, Michel LO, Zhang Q. CmeABC functions as a multidrug efflux system in *Campylobacter*
661 *jejuni*. *Antimicrob Agents Chemother.* juill 2002;46(7):2124-31.
- 662 53. Akiba M, Lin J, Barton YW, Zhang Q. Interaction of CmeABC and CmeDEF in conferring
663 antimicrobial resistance and maintaining cell viability in *Campylobacter jejuni*. *Journal of*
664 *Antimicrobial Chemotherapy.* 1 janv 2006;57(1):52-60.
- 665 54. Pumbwe L, Randall LP, Woodward MJ, Piddock LJV. Evidence for Multiple-Antibiotic Resistance
666 in *Campylobacter jejuni* Not Mediated by CmeB or CmeF. *Antimicrob Agents Chemother.* avr
667 2005;49(4):1289-93.
- 668 55. Reeser RJ, Medler RT, Billington SJ, Jost BH, Joens LA. Characterization of *Campylobacter jejuni*
669 biofilms under defined growth conditions. *Appl Environ Microbiol.* mars 2007;73(6):1908-13.
- 670 56. Reichelt B, Szott V, Stingl K, Roesler U, Friese A. Detection of Viable but Non-Culturable (VBNC)-
671 *Campylobacter* in the Environment of Broiler Farms: Innovative Insights Delivered by Propidium
672 Monoazide (PMA)-v-qPCR Analysis. *Microorganisms.* 4 oct 2023;11(10):2492.
- 673 57. Monteiro MA, Baqar S, Hall ER, Chen YH, Porter CK, Bentzel DE, et al. Capsule polysaccharide
674 conjugate vaccine against diarrheal disease caused by *Campylobacter jejuni*. *Infect Immun.* mars
675 2009;77(3):1128-36.
- 676 58. Li Z, Clarke AJ, Beveridge TJ. Gram-negative bacteria produce membrane vesicles which are
677 capable of killing other bacteria. *J Bacteriol.* oct 1998;180(20):5478-83.
- 678 59. Gill S, Catchpole R, Forterre P. Extracellular membrane vesicles in the three domains of life and
679 beyond. *FEMS Microbiol Rev.* 1 mai 2019;43(3):273-303.

- 680 60. Ñahui Palomino RA, Vanpouille C, Costantini PE, Margolis L. Microbiota-host communications:
681 Bacterial extracellular vesicles as a common language. *PLoS Pathog.* mai 2021;17(5):e1009508.
- 682 61. Hendrix A, De Wever O. Systemically circulating bacterial extracellular vesicles: origin, fate, and
683 function. *Trends Microbiol.* mars 2022;30(3):213-6.
- 684 62. Bitto NJ, Chapman R, Pidot S, Costin A, Lo C, Choi J, et al. Bacterial membrane vesicles transport
685 their DNA cargo into host cells. *Sci Rep.* 1 août 2017;7(1):7072.
- 686 63. Lindmark B, Rompikuntal PK, Vaitkevicius K, Song T, Mizunoe Y, Uhlin BE, et al. Outer membrane
687 vesicle-mediated release of cytolethal distending toxin (CDT) from *Campylobacter jejuni*. *BMC*
688 *Microbiol.* 16 oct 2009;9:220.
- 689 64. Toyofuku M, Schild S, Kaparakis-Liaskos M, Eberl L. Composition and functions of bacterial
690 membrane vesicles. *Nat Rev Microbiol.* juill 2023;21(7):415-30.
- 691 65. Pérez-Cruz C, Delgado L, López-Iglesias C, Mercade E. Outer-inner membrane vesicles naturally
692 secreted by gram-negative pathogenic bacteria. *PLoS One.* 2015;10(1):e0116896.
- 693 66. Baidya AK, Bhattacharya S, Dubey GP, Mamou G, Ben-Yehuda S. Bacterial nanotubes: a conduit
694 for intercellular molecular trade. *Curr Opin Microbiol.* avr 2018;42:1-6.
- 695 67. Mashburn-Warren L, Howe J, Garidel P, Richter W, Steiniger F, Roessle M, et al. Interaction of
696 quorum signals with outer membrane lipids: insights into prokaryotic membrane vesicle
697 formation. *Mol Microbiol.* juill 2008;69(2):491-502.
- 698 68. Elhenawy W, Bording-Jorgensen M, Valguarnera E, Haurat MF, Wine E, Feldman MF. LPS
699 Remodeling Triggers Formation of Outer Membrane Vesicles in *Salmonella*. *mBio.* 12 juill
700 2016;7(4):e00940-16.
- 701 69. Brennan CA, Hunt JR, Kremer N, Krasity BC, Apicella MA, McFall-Ngai MJ, et al. A model symbiosis
702 reveals a role for sheathed-flagellum rotation in the release of immunogenic lipopolysaccharide.
703 *Elife.* 4 mars 2014;3:e01579.
- 704 70. Roier S, Zingl FG, Cakar F, Durakovic S, Kohl P, Eichmann TO, et al. A novel mechanism for the
705 biogenesis of outer membrane vesicles in Gram-negative bacteria. *Nat Commun.* 25 janv
706 2016;7:10515.
- 707 71. Davies C, Taylor AJ, Elmi A, Winter J, Liaw J, Grabowska AD, et al. Sodium Taurocholate Stimulates
708 *Campylobacter jejuni* Outer Membrane Vesicle Production via Down-Regulation of the
709 Maintenance of Lipid Asymmetry Pathway. *Front Cell Infect Microbiol.* 2019;9:177.
- 710 72. Gabbert AD, Mydosh JL, Talukdar PK, Gloss LM, McDermott JE, Cooper KK, et al. The Missing
711 Pieces: The Role of Secretion Systems in *Campylobacter jejuni* Virulence. *Biomolecules.* 9 janv
712 2023;13(1):135.
- 713 73. Lertpiriyapong K, Gamazon ER, Feng Y, Park DS, Pang J, Botka G, et al. *Campylobacter jejuni* Type
714 VI Secretion System: Roles in Adaptation to Deoxycholic Acid, Host Cell Adherence, Invasion, and
715 In Vivo Colonization. *PLoS One.* 27 août 2012;7(8):e42842.
- 716 74. Elmi A, Watson E, Sandu P, Gundogdu O, Mills DC, Inglis NF, et al. *Campylobacter jejuni* outer
717 membrane vesicles play an important role in bacterial interactions with human intestinal
718 epithelial cells. *Infect Immun.* déc 2012;80(12):4089-98.

- 719 75. Jinadasa RN, Bloom SE, Weiss RS, Duhamel GE. Cytolethal distending toxin: a conserved bacterial
720 genotoxin that blocks cell cycle progression, leading to apoptosis of a broad range of mammalian
721 cell lineages. *Microbiology (Reading)*. juill 2011;157(Pt 7):1851-75.
- 722 76. Le LHM, Elgamoudi B, Colon N, Cramond A, Poly F, Ying L, et al. *Campylobacter jejuni* extracellular
723 vesicles harboring cytolethal distending toxin bind host cell glycans and induce cell cycle arrest
724 in host cells. *Blondel CJ, éditeur. Microbiol Spectr*. 5 mars 2024;12(3):e03232-23.
- 725 77. Sałamaszyńska-Guz A, Rasmussen PK, Murawska M, Douthwaite S. *Campylobacter jejuni*
726 Virulence Factors Identified by Modulating Their Synthesis on Ribosomes With Altered rRNA
727 Methylation. *Front Cell Infect Microbiol*. 2021;11:803730.
- 728 78. Elmi A, Nasher F, Jagatia H, Gundogdu O, Bajaj-Elliott M, Wren B, et al. *Campylobacter jejuni*
729 outer membrane vesicle-associated proteolytic activity promotes bacterial invasion by mediating
730 cleavage of intestinal epithelial cell E-cadherin and occludin. *Cell Microbiol*. avr
731 2016;18(4):561-72.
- 732 79. Jang KS, Sweredoski MJ, Graham RLJ, Hess S, Clemons WM. Comprehensive proteomic profiling
733 of outer membrane vesicles from *Campylobacter jejuni*. *J Proteomics*. 26 févr 2014;98:90-8.
- 734 80. Taheri N, Mahmud AKMF, Sandblad L, Fällman M, Wai SN, Fahlgren A. *Campylobacter jejuni* bile
735 exposure influences outer membrane vesicles protein content and bacterial interaction with
736 epithelial cells. *Sci Rep*. 19 nov 2018;8(1):16996.
- 737 81. Taheri N, Fällman M, Wai SN, Fahlgren A. Accumulation of virulence-associated proteins in
738 *Campylobacter jejuni* Outer Membrane Vesicles at human body temperature. *J Proteomics*. 20
739 mars 2019;195:33-40.
- 740 82. Godlewska R, Klim J, Dębski J, Wszyńska A, Łasica A. Influence of Environmental and Genetic
741 Factors on Proteomic Profiling of Outer Membrane Vesicles from *Campylobacter jejuni*. *Pol J*
742 *Microbiol*. 2019;68(2):255-61.
- 743 83. Akahoshi DT, Bevins CL. Flagella at the Host-Microbe Interface: Key Functions Intersect With
744 Redundant Responses. *Front Immunol*. 24 mars 2022;13:828758.
- 745 84. Duan Q, Zhou M, Zhu L, Zhu G. Flagella and bacterial pathogenicity. *J Basic Microbiol*. janv
746 2013;53(1):1-8.
- 747 85. Ruby J, Martin M, Passineau MJ, Godovikova V, Fenno JC, Wu H. Activation of the Innate Immune
748 System by *Treponema denticola* Periplasmic Flagella through Toll-Like Receptor 2. *Infect Immun*.
749 janv 2018;86(1):e00573-17.
- 750 86. Wszyńska A, Życka J, Godlewska R, Jagusztyn-Krynicka EK. The *Campylobacter jejuni*/colicjaA
751 (cj0982c) Gene Encodes an N-Glycosylated Lipoprotein Localized in the Inner Membrane. *Curr*
752 *Microbiol*. 1 sept 2008;57(3):181-8.
- 753 87. Elmi A, Dorey A, Watson E, Jagatia H, Inglis NF, Gundogdu O, et al. The bile salt sodium
754 taurocholate induces *Campylobacter jejuni* outer membrane vesicle production and increases
755 OMV-associated proteolytic activity. *Cellular Microbiology*. 2018;20(3):e12814.
- 756 88. Khan A, Sardar A, Tarafdar PK, Mallick AI. Heterogeneity and Compositional Diversities of
757 *Campylobacter jejuni* Outer Membrane Vesicles (OMVs) Drive Multiple Cellular Uptake
758 Processes. *ACS Infect Dis*. 10 nov 2023;9(11):2325-39.

759 89. Farace P, Cravero S, Taibo C, Diodati J, Morsella C, Paolicchi F, et al. Campylobacter fetus releases
760 S-layered and immunoreactive outer membrane vesicles. Rev Argent Microbiol.
761 2022;54(2):74-80.

762 90. Godlewska R, Kuczkowski M, Wszyńska A, Klim J, Derlatka K, Woźniak-Biel A, et al. Evaluation of
763 a protective effect of in ovo delivered Campylobacter jejuni OMVs. Appl Microbiol Biotechnol.
764 oct 2016;100(20):8855-64.

765

766